用免疫检查点抑制剂(ICIS)的治疗表明了针对各种癌症类型的疗效。使用抗PD-1,抗PD-L1和抗CTLA-4抗体正在迅速膨胀。ICIS的副作用与常规的细胞癌抗癌和分子靶药物非常不同,并且可以延伸到消化器官,呼吸道器官,甲状腺,垂体腺,皮肤等。虽然这些不良事件的细节变得越来越明显,但对于感染有关的效果和不良事件,许多是不明的。该评论专注于ICIS对呼吸道感染的影响。The impact of ICIs on pathogens varies depending on the significance of the role of T-cell immunity in the immune response to the specific pathogen, as well as the different modes of infection (i.e., acute or chronic), although the impact of ICIs on the clinical outcome of infections in humans has not yet been well studied. Enhanced clearance of many pathogens has been shown because immune checkpoint inhibition activates T cells. In contrast, reactivation of tuberculosis associated with ICI use has been reported, and therefore caution is warranted. In COVID-19 pneumonia, ICI administration may lead to exacerbation; however, it is also possible that ICI may be used for the treatment of COVID-19. It has also been shown that ICI has potential in the treatment of intractable filamentous fungal infections. Therefore, expanded clinical applications are expected.
版权所有©2020 Elsevier Ltd.保留所有权利。
用于最新消息和更新